The ‘Gift of Time’ will see EirGen Pharma avail of mentoring and business advice from some of the country’s leading experts in key business fields such as finance, marketing, identity and brand management, public relations, legal advice, as well as places on training programmes in marketing and management and membership of the Dublin Chamber of Commerce. EirGen Pharma also received €10,000 in cash.

Gerry O’Reilly, Chairman, David Manley Award Committee, commented, “Our Award is very different from other entrepreneur awards for a number of reasons. Firstly, it is targeted at identifying high potential entrepreneurs to help them accelerate their plans. Secondly, it is the largest award and we operate nationwide. Thirdly, we are independent of any college and cover all entrepreneurs across three sectors of life – business, the arts and social/community. And finally, but most important of all, the winner receives the ‘gift of time’ – €80,000 worth of mentoring and consultancy from a selection of top companies.”

For more click the following link: EOA Awards Press Release (pdf)

In announcing the deal Patsy Carney expressed his gratitude to Enterprise Ireland who made the initial introduction between EirGen Pharma and Three Rivers Pharma. “Enterprise Ireland is an invaluable resource to clients like EirGen Pharma and we thank them for their continued support. We are delighted to be partnering with Three Rivers Pharma as there is a strategic fit between EirGen Pharma’s high potency product development and manufacturing capabilities and Three Rivers Pharma’s proven ability to successfully market niche pharmaceutical products in the United States.”

Commenting on the agreement, Donald Kerrish, President and CEO, stated that “Three Rivers Pharmaceuticals embraces the opportunity presented to us in our new and exciting partnership with EirGen Pharma. EirGen Pharma’s unprecedented reputation for the research, development and manufacturing of high potency solid dose products combined with Three Rivers Pharmaceuticals highly-recognized reputation for marketing these types of products will allow both companies to prosper within the pharmaceutical industry.”

For more click the following link: Irish Independent Article

Under the terms of the agreement, EirGen Pharma will exclusively develop and commercially supply these products to Corepharma for the US market. The companies have agreed to collaborate for the development and commercialisation of two products with a current market value in excess of $300 million. The companies are also evaluating the potential of developing another three products with current US sales of over $1.5 Billion.

Gregory Young, CEO of Corepharma stated that “The addition of new products into our collaboration with EirGen Pharma is a measure of our confidence in their ability to achieve the desired milestones. It is also a reflection of our continuing commitment to bring therapeutically important, high value products to the US market.” Patsy Carney, CEO of EirGen Pharma commented that “We have an established relationship with Corepharma and this latest opportunity is a measure of the success of the existing collaborations. We look forward to continuing to work with Corepharma to successfully commercialise the full portfolio of products.”

Containment technology forum solutions resources

For more information click on http://www.cphi.com/

Carney and Brennan graduated from the UL corporate MBA programme in December 2005 and Prof. Patricia Fleming, Programme Director, commented, “EirGen is a fine example of translating business planning into reality and we look forward to many more start-ups coming from the MBA programme.”

EirGen Pharma is a pharmaceutical company based in Waterford, Ireland. Using its purpose built high containment facility; the company specialises in the development, registration and manufacture of high potency solid dose products for global markets.

EirGen Pharma is a pharmaceutical company based in Waterford, Ireland. Using its purpose built high containment facility; the company specialises in the development, registration and manufacture of high potency solid dose products for global markets

EirGen Pharma`s Technical Director Tom Brennan stated that "this is a significant achievement for EirGen as it continues to demonstrate our committment to delivering innovative high potency pharmaceutical products for global markets". Managing Director Patsy Carney commented "this latest successful clinical trial highlights EirGen`s ability to deliver niche products and adds to our portfolio of oncology molecules across multiple markets".

EirGen Pharma is a pharmaceutical company based in Waterford, Ireland. Using its purpose built high containment facility; the company specialises in the development, registration and manufacture of high potency solid dose products for global markets

EirGen Pharma is a pharmaceutical company based in Waterford, Ireland. Using its purpose built high containment facility; the company specialises in the development, registration and manufacture of high potency solid dose products for global markets.

Tom is presenting EirGen Pharma`s case studies update on both "Cleaning Verification" and "Risk Analysis" in conjunction with representatives from Industry and US FDA. Please follow links below for more information:

http://www.ispe.org/cs/root/education_and_training/events/2008_washington_conferences/cleaning_for_the_21st_century_science_and_riskbased_approaches

http://www.ispe.org/cs/root/education_and_training/events/2008_washington_conferences/riskmapp_application_of_the_new_riskmapp_ispe_baseline_guide

EirGen Pharma is a pharmaceutical company based in Waterford, Ireland. Using its purpose built high containment facility; the company specialises in the development, registration and manufacture of high potency solid dose products for global markets.

EirGen Pharma is a pharmaceutical company based in Waterford, Ireland. Using its purpose built high containment facility; the company specialises in the development, registration and manufacture of high potency solid dose products for global markets.

EirGen Pharma is a pharmaceutical company based in Waterford, Ireland. Using its purpose built high containment facility; the company specialises in the development, registration and manufacture of high potency solid dose products for global markets.

For more information click on http://www.cphi.com/

EirGen Pharma is a pharmaceutical company based in Waterford, Ireland. Using its purpose built high containment facility; the company specialises in the development, registration and manufacture of high potency solid dose products for global markets.

EirGen Pharma is a pharmaceutical company based in Waterford, Ireland. Using its purpose built high containment facility; the company specialises in the development, registration and manufacture of high potency solid dose products for global markets.

EirGen Pharma is a pharmaceutical company based in Waterford, Ireland. Using its purpose built high containment facility; the company specialises in the development, registration and manufacture of high potency solid dose products for global markets.

http://www.taoiseach.gov.ie/eng/Innovation_Taskforce/

EirGen Pharma`s Technical Director Tom Brennan stated that "this is a significant achievement for EirGen as it continues to demonstrate our committment to delivering innovative high potency pharmaceutical products for global markets". Managing Director Patsy Carney commented "this latest successful clinical trial highlights EirGen`s ability to deliver niche products and adds to our portfolio of oncology molecules across multiple markets".

EirGen Pharma is a pharmaceutical company based in Waterford, Ireland. Using its purpose built high containment facility; the company specialises in the development, registration and manufacture of high potency solid dose products for global markets.

EirGen Pharma is a pharmaceutical company based in Waterford, Ireland. Using its purpose built high containment facility; the company specialises in the development, registration and manufacture of high potency solid dose products for global markets.

QUMAS DocCompliance and ProcessCompliance will provide EirGen Pharma with an integrated solution to improve document control and reduce approval lifecycles of regulatory documents. EirGen Pharma will also use the integrated solution to automate Change Control and Non-Conformance Management to drive efficiencies across both processes. EirGen Pharma will roll out the QUMAS solution to all employees.

"EirGen as a business is scaling rapidly and needs the infrastructure to support this growth. From a documentation control and compliance perspective, QUMAS provides the solution to this challenge," said Patsy Carney, Managing Director at EirGen Pharma. "QUMAS has provided us with a cost effective and flexible solution that addresses our compliance issues today, and can be expanded to meet our future needs."

"Our solution will provide EirGen with a single platform to manage all of their compliance programs," stated Kevin O`Leary, CEO of QUMAS. "This will enable EirGen to dramatically reduce their compliance costs and create a competitive advantage."

The go-live of QUMAS follows on from the successful implementation of SAP in June 2010 to manage operation planning and requisitions to support future growth of the organisation.

EirGen Pharma is a pharmaceutical company based in Waterford, Ireland. Using its purpose built high containment facility; the company specializes in the development, registration and manufacture of high potency solid dose products for global markets.

Technical Director Tom Brennan stated that "this is a very significant achievement for us with this key product that passed clinical trial in February 2010. This builds on our product approval last year for another early-stage cancer treatment which is on sale in Canada since early 2010". Managing Director Patsy Carney stated that "another key milestone reached for EirGen with our second Canadian submission".

EirGen Pharma is a pharmaceutical company based in Waterford, Ireland. Using its purpose built high containment facility; the company specialises in the development, registration and manufacture of high potency solid dose products for global markets.